Pii to Manufacture FDA-Approved Hormone Therapy Injection Drug Product
HUNT VALLEY, Md., Sept. 23, 2019 /PRNewswire/ -- Pharmaceutics International, Inc. (Pii), a Contract Development and Manufacturing Organization (CDMO) headquartered in Hunt Valley, Maryland, is pleased to announce the commercial supply of Fulvestrant Injection 250mg/5ml drug product, which was recently approved by the FDA. Pii will be responsible for all commercial drug product production and Sagent Pharmaceuticals, the ANDA holder, will sell, market and distribute the drug product in the U.S.
"We are pleased to support Sagent Pharmaceuticals in its efforts to supply an affordable treatment option for post-menopausal patients suffering from breast cancer. Pii's Pharmaceutics Know-How™ has once again proven valuable to one of our partners, as they strive to develop and provide approved drug products to patients in need. Fulvestrant Injection 250mg/5ml drug product is the 5th injectable product approved and produced by Pii, during the past two years," said Dr. Kurt Nielsen, Pii's President and CEO.
About Pharmaceutics International, Inc.
Pii is a privately held CDMO providing dosage form development and cGMP manufacturing services to the global pharmaceutical industry. Headquartered in Hunt Valley, Maryland USA, Pii's services include pre-formulation development, and clinical and commercial cGMP manufacturing of parenterals, liquid solutions and oral solids, including soft gels, tablets and capsules. In addition, the Company offers containment suites to handle potent drugs and Schedules I-V controlled substances. For more information, please visit www.pharm-int.com.
Contact:
Kurt R. Nielsen, Ph.D., President and CEO
Pharmaceutics International, Inc.
10819 Gilroy Road
Hunt Valley, MD 21031
Phone: (410) 584-0001
Email: [email protected]
SOURCE Pharmaceutics International, Inc.
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article